Chapter 1.QUINOLONES MARKET – Scope & Methodology

1.1. Market Segmentation

1.2. Assumptions

1.3. Research Methodology

1.4. Primary Sources

1.5. Secondary Sources

Chapter 2.QUINOLONES MARKET– Executive Summary

2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)

2.2. Key Trends & Insights

2.3. COVID-1 Impact Analysis

      2.3.1. Impact during 2023 - 2030

      2.3.2. Impact on Supply – Demand

Chapter 3.QUINOLONES MARKET – Competition Scenario

3.1. Market Share Analysis

3.2. Product Benchmarking

3.3. Competitive Strategy & Development Scenario

3.4. Competitive Pricing Analysis

3.5. Supplier - Distributor Analysis

Chapter 4.QUINOLONES MARKET - Entry Scenario

4.1. Case Studies – Start-up/Thriving Companies

4.2. Regulatory Scenario - By Region

4.3 Customer Analysis

4.4. Porter's Five Force Model

       4.4.1. Bargaining Power of Suppliers

       4.4.2. Bargaining Powers of Customers

       4.4.3. Threat of New Entrants

       4.4.4. Rivalry among Existing Players

       4.4.5. Threat of Substitutes

Chapter 5. QUINOLONES MARKET - Landscape

5.1. Value Chain Analysis – Key Stakeholders Impact Analysis

5.2.  Market Drivers

5.3. Market Restraints/Challenges

5.4. Market Opportunities

Chapter 6.QUINOLONES MARKET – By Action Mechanism

6.1. Cell Wall Synthesis Inhibitors

6.2. Protein Synthesis Inhibitors

6.3. DNA Synthesis Inhibitors

6.4. RNA Synthesis Inhibitors

6.5. Mycolic Acid Inhibitors

6.6. Others

Chapter 7.QUINOLONES MARKET – By Drug Class

7.1.  Cephalosporin

7.2.·Penicillin

7.3. Fluoroquinolon

7.4.  Macrolide

7.5.  Carbapenem

7.6. Aminoglycoside

7.7. Sulfonamide   

7.8. 7-.AC

7.9. Others

Chapter 9.QUINOLONES MARKET – By Region

9.1. North America

9.2. Europe

9.3. The Asia Pacific

9.4. Latin America

9.5. The Middle East

9.6. Africa

Chapter 10. QUINOLONES MARKET – Key Players

10.1. Bayer AG

10.2. Merck & Co

10.3. ALLERGAN

10.4. Pfizer Inc

10.5. Novartis AG

10.6. LG Chem

10.7. Mylan N.V,

10.9 Lupin

10.9. Hitech

10.10. Amneal Pharmaceuticals LLC

10.11. Zydus Cadila

10.12. Bausch Health

10.13. Teva Pharmaceutical Industries Ltd,

10.14. Akron Incorporated

10.15. KYORIN Holdings

10.16. MerLion Pharmaceuticals GmbH

10.17. Wockhardt

10.18. Johnson & Johnson Services

10.19. Sanofi